INNATE PHARMA SP.ADR/1 Market Cap ($116.15 Million)
Market Cap & Net Worth: INNATE PHARMA SP.ADR/1 (IDDA)
INNATE PHARMA SP.ADR/1 market cap. INNATE PHARMA SP.ADR/1 (F:IDDA) has a market capitalization of $116.15 Million (€99.35 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #18428 globally and #1709 in its home market, demonstrating a -26.90% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying INNATE PHARMA SP.ADR/1's stock price €1.06 by its total outstanding shares 93724668 (93.72 Million). Also see INNATE PHARMA SP.ADR/1 (IDDA) cash flow conversion for how efficiently the company converts equity into cash flow.
INNATE PHARMA SP.ADR/1 Market Cap History (2019–2026)
INNATE PHARMA SP.ADR/1 market cap history from 2019 to 2026. Data shows change from $608.14 Million to $121.63 Million (-22.29% CAGR). Check INNATE PHARMA SP.ADR/1 stock price for real-time trading data and today's change.
INNATE PHARMA SP.ADR/1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how INNATE PHARMA SP.ADR/1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore INNATE PHARMA SP.ADR/1 (IDDA) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
57.01x
INNATE PHARMA SP.ADR/1's market cap is 57.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $429.53 Million | $12.11 Million | -$52.81 Million | 35.47x | N/A |
| 2022 | $352.83 Million | $49.58 Million | -$58.10 Million | 7.12x | N/A |
| 2023 | $273.93 Million | $51.90 Million | -$7.57 Million | 5.28x | N/A |
| 2024 | $204.90 Million | $12.62 Million | -$49.47 Million | 16.24x | N/A |
| 2025 | $158.88 Million | $2.79 Million | -$49.18 Million | 57.01x | N/A |
Competitor Companies of IDDA by Market Capitalization
Companies near INNATE PHARMA SP.ADR/1 in the global market cap rankings as of November 4, 2026. Also see IDDA total asset value for a full breakdown of the balance sheet.
Key companies related to INNATE PHARMA SP.ADR/1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of INNATE PHARMA SP.ADR/1 (2019–2026)
Market capitalization of INNATE PHARMA SP.ADR/1 from 2019 to today. Between 2019 and today, INNATE PHARMA SP.ADR/1's market cap moved from $608.14 Million to $ 121.63 Million, with a yearly change of -22.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €121.63 Million | -23.45% |
| 2025 | €158.88 Million | -22.46% |
| 2024 | €204.90 Million | -25.20% |
| 2023 | €273.93 Million | -22.36% |
| 2022 | €352.83 Million | -17.86% |
| 2021 | €429.53 Million | +24.05% |
| 2020 | €346.25 Million | -43.06% |
| 2019 | €608.14 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of INNATE PHARMA SP.ADR/1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $116.15 Million USD |
| MoneyControl | $116.15 Million USD |
| MarketWatch | $116.15 Million USD |
| marketcap.company | $116.15 Million USD |
| Reuters | $116.15 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About INNATE PHARMA SP.ADR/1
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Mo… Read more